Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

26.02
-1.1600-4.27%
Post-market: 25.98-0.0377-0.14%19:53 EST
Volume:1.79M
Turnover:46.89M
Market Cap:1.35B
PE:-14.41
High:27.12
Open:26.55
Low:25.59
Close:27.18
52wk High:40.37
52wk Low:4.30
Shares:51.72M
Float Shares:46.19M
Volume Ratio:0.49
T/O Rate:3.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8055
EPS(LYR):-1.1490
ROE:-107.79%
ROA:-49.39%
PB:16.05
PE(LYR):-22.65

Loading ...

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Benzinga_recent_news
·
Dec 04

Capricor Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 04

BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox

Reuters
·
Dec 04

Stock Track | Capricor Therapeutics Soars 383% as Duchenne Therapy Meets Phase 3 Goals

Stock Track
·
Dec 04

Capricor Therapeutics on Track for Highest Close Since October 2017 -- Data Talk

Dow Jones
·
Dec 04

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

Benzinga
·
Dec 04

Capricor Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $60 From $24

THOMSON REUTERS
·
Dec 04

BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics

Reuters
·
Dec 03

BUZZ-Capricor jumps to 8-year high as cell therapy slows muscle-wasting disease

Reuters
·
Dec 03

Capricor Shares Gain Six-Fold to $40 After Co's Muscle Disorder Cell Therapy Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Dec 03

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM

Reuters
·
Dec 03

Sector Update: Health Care Stocks Advance Premarket Wednesday

MT Newswires Live
·
Dec 03

Capricor Therapeutics Exec Believes It Is "Prepared to Launch" Deramiocel - Conf Call

THOMSON REUTERS
·
Dec 03

Capricor Therapeutics Exec Says Co Passed Pre Licensing Inspection for San Diego Manufacturing Facility

THOMSON REUTERS
·
Dec 03

Capricor Exec Says FDA Indicated It Would Be Class Two Resubmission, Which Is About Six Months

THOMSON REUTERS
·
Dec 03

Capricor Exec Says Deramiocel Can Be Used With Any Therapeutics Currently Approved, Available or Under Clinical Development

THOMSON REUTERS
·
Dec 03

Capricor Exec Says Co Will Certainly Ask for Label for Skeletal Muscle Myopathy Based on Data

THOMSON REUTERS
·
Dec 03

Capricor Shares up 15% Premarket After Co's Muscle Disorder Cell Therapy Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Dec 03

BRIEF-Capricor Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Hope-3 Study

Reuters
·
Dec 03

Capricor eyes US nod for Duchenne cell therapy after success in key study

Reuters
·
Dec 03